PROSE treatment of corneal ectasia

Baran, Inna; Bradley, James; Alipour, Fateme; Rosenthal, Perry; Le, Hong-Gam; Jacobs, Deborah S.

doi:10.1016/j.clae.2012.04.003

Cited by 74 publications

(59 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3 In a study of a 6-month follow-up in corneal ectasia patients, 88% (78/89 eyes) were still wearing their PROSE lens at 6 months with no reports of infection. 4 More studies are needed to assess an association between ocular infection and PROSE lens use, but there are no prior reports of AK in PROSE users.…”

Section: Discussionmentioning

confidence: 99%

Deep Anterior Lamellar Keratoplasty for Acanthamoeba Keratitis Complicating the Use of Boston Scleral Lens

Farhat

Sutphin²

2014

Eye &Amp; Contact Lens: Science &Amp; Clinical Practice

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Deep Anterior Lamellar Keratoplasty for Acanthamoeba Keratitis Complicating the Use of Boston Scleral Lens

Farhat

Sutphin²

2014

Eye &Amp; Contact Lens: Science &Amp; Clinical Practice

View full text Add to dashboard Cite

show abstract

“…9 Experience in the paediatric age group has also been reported. 10 PROSE treatment has been shown to be cost effective in terms of health benefit to the patient.…”

Section: Introductionmentioning

confidence: 99%

Prosthetic replacement of the ocular surface ecosystem: impact at 5 years

2015

View full text Add to dashboard Cite

Background/aimsTo determine the impact of prosthetic replacement of the ocular surface ecosystem (PROSE) treatment at 5 years.MethodsRetrospective review of clinical, manufacturing and quality databases at the Boston Foundation for Sight.Results121 patients who completed treatment and had 5-year follow-up data were identified from a cohort of patients (n=199) seen in consultation for PROSE treatment from January 2008 to June 2008. Mean age was 52 years, M:F=56:65. The primary indication for treatment was ocular surface disease (OSD) in 64 patients and distorted corneal surface in 57 patients. At 5 years, continued device wear was confirmed in 89/121 (73.6%) patients. Discontinuation of wear was confirmed in 32/121 (26.4%). There was an increased likelihood of continued device wear at 5 years in patients with distorted cornea (84%) compared with those with OSD (64%), (p=0.0121, χ2). National Eye Institute Visual Function Questionnaire (NEI VFQ-25) composite score increased for patients wearing PROSE devices at 6 months (Δ=+23 points, mean=82, p<0.001, two-tailed t test) with no significant decline among those still wearing a device at 5 years (Δ=−4 points, mean=78, p=0.22, two-tailed t test). At 5 years, those wearing (mean=78) had a higher NEI VFQ-25 than those not wearing (mean=70, p=0.029, two-tailed t test).ConclusionsPROSE treatment offers continued benefit, as defined by improved visual function and continued device wear at 5 years, in patients with complex corneal disease. Patients with distorted cornea have a higher rate of continued wear at 5 years than patients with OSD, although this is not true among all subgroups within OSD.

show abstract

“…12 A large impact across the spectrum of complex corneal disease has been reported in recent years, 8,13 as has a high success rate and large impact on visual function in advanced keratoconus. 14 In this retrospective study, we report the impact of PROSE treatment in a large series of patients with chronic ocular surface disease related to SJS/TEN.…”

mentioning

confidence: 99%